MX386373B - Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer. - Google Patents

Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.

Info

Publication number
MX386373B
MX386373B MX2020008039A MX2020008039A MX386373B MX 386373 B MX386373 B MX 386373B MX 2020008039 A MX2020008039 A MX 2020008039A MX 2020008039 A MX2020008039 A MX 2020008039A MX 386373 B MX386373 B MX 386373B
Authority
MX
Mexico
Prior art keywords
cells
natural killer
composition
producing natural
cancer treatment
Prior art date
Application number
MX2020008039A
Other languages
English (en)
Spanish (es)
Other versions
MX2020008039A (es
Inventor
Jae Seob Jung
Sang Woo Park
Yong Man Kim
Yong-Hee Rhee
Original Assignee
Nkmax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190001981A external-priority patent/KR102732845B1/ko
Priority claimed from KR1020190001983A external-priority patent/KR102765799B1/ko
Application filed by Nkmax Co Ltd filed Critical Nkmax Co Ltd
Priority claimed from PCT/US2019/016076 external-priority patent/WO2019152663A1/en
Publication of MX2020008039A publication Critical patent/MX2020008039A/es
Publication of MX386373B publication Critical patent/MX386373B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2020008039A 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer. MX386373B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20180012938 2018-02-01
KR20180012942 2018-02-01
KR1020190001981A KR102732845B1 (ko) 2018-02-01 2019-01-07 자연살해세포의 생산방법
KR1020190001983A KR102765799B1 (ko) 2018-02-01 2019-01-07 Cd56+ 자연살해세포를 포함하는 항암용 조성물
PCT/US2019/016076 WO2019152663A1 (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer

Publications (2)

Publication Number Publication Date
MX2020008039A MX2020008039A (es) 2021-09-20
MX386373B true MX386373B (es) 2025-03-18

Family

ID=68465207

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008039A MX386373B (es) 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
MX2021004682A MX2021004682A (es) 2018-02-01 2020-07-30 Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021004682A MX2021004682A (es) 2018-02-01 2020-07-30 Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.

Country Status (15)

Country Link
US (4) US10590385B2 (enExample)
EP (1) EP3746095A4 (enExample)
JP (3) JP7268039B2 (enExample)
CN (2) CN111757745B (enExample)
AU (2) AU2019215034C1 (enExample)
BR (1) BR112020015512A2 (enExample)
CA (1) CA3089853A1 (enExample)
CL (1) CL2020002011A1 (enExample)
IL (1) IL276365B2 (enExample)
MX (2) MX386373B (enExample)
MY (2) MY199514A (enExample)
NZ (1) NZ766453A (enExample)
PH (1) PH12020551151A1 (enExample)
SA (1) SA520412566B1 (enExample)
SG (1) SG11202007221QA (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) * 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
KR102623244B1 (ko) 2016-12-21 2024-01-09 주식회사 엔케이맥스 면역 세포 및 포나티닙을 포함하는 약학 조성물 및 방법
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP2023505102A (ja) * 2019-11-29 2023-02-08 エヌケーマックス カンパニー リミテッド ナチュラルキラー細胞を製造する方法およびその組成物
CN112626029B (zh) * 2020-12-22 2022-12-20 深圳市赛欧细胞技术有限公司 一种转基因修饰的Daudi细胞及其制备方法、应用
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
WO2024036226A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
CN116904397B (zh) * 2023-09-04 2023-12-26 山东德升细胞治疗工程技术有限公司 Nk细胞的细胞外囊泡的制备及应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320906C (en) 1986-06-04 1993-08-03 Daniel R. Twardzik Interleukin-2 induced antineoplastic peptide
JPH04503607A (ja) 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
GR1001034B (el) 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
WO1998005795A1 (en) 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20040173778A1 (en) 2001-05-30 2004-09-09 Roncarolo Maria Grazia Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
ES2381265T3 (es) 2002-06-07 2012-05-24 Zymogenetics, Inc. Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos
ATE414176T1 (de) 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
US20050191743A1 (en) 2002-10-03 2005-09-01 Wu J.H. D. Three-dimensional peripheral lymphoid organ cell cultures
JP4033390B2 (ja) 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
EP1755685A4 (en) 2004-05-28 2008-11-12 Mayo Foundation METHODS FOR TRANSPLANTATION OF AUTOLOGOUS STEM CELLS
WO2006050270A2 (en) 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
RU2394561C2 (ru) 2004-11-24 2010-07-20 Хилл`С Пет Ньютришн, Инк. Способы увеличения иммунного ответа у животного
CA2601197C (en) 2005-03-17 2017-06-06 Ucl Biomedica Plc Method
DK1739166T3 (da) 2005-07-01 2011-10-10 Txcell S A Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
DK1941027T3 (da) 2005-09-28 2014-10-13 Ipd Therapeutics B V Fremgangsmåder og midler til stamcelleforøgelse og efterfølgende generering og ekspansion af progenitorceller samt produktion af effektorceller som kliniske terapeutika
WO2007103901A2 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
WO2008118369A2 (en) 2007-03-22 2008-10-02 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
EP2142642B1 (en) 2007-03-27 2017-08-09 IPD-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics
KR100902340B1 (ko) 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
EP2433713B1 (en) 2007-12-07 2017-07-26 Miltenyi Biotec GmbH Cell processing systems and methods
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
CN102428173B (zh) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Nk细胞的扩增
TW201127959A (en) 2010-02-12 2011-08-16 Ivy Life Sciences Co Ltd Method of producing immune killer cell
AU2010347018A1 (en) 2010-02-24 2012-09-20 Ingo Schmidt-Wolf Method for the generation of a CIK cell and NK cell population
KR20230096132A (ko) 2010-07-13 2023-06-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
KR101145391B1 (ko) 2010-08-16 2012-05-15 고려대학교 산학협력단 말초혈액으로부터 자연 살해세포의 증식 방법
TWI439275B (zh) 2010-12-31 2014-06-01 Glory Biomedical Co Ltd 一種人類自然殺手細胞之體外增殖方法
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
US11118165B2 (en) 2011-03-18 2021-09-14 Glycostem Therapeutics B.V. Generation of NK cells and NK-cell progenitors
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
NO2794859T3 (enExample) 2011-12-22 2018-02-17
CA2864283C (en) 2012-02-08 2020-11-03 Jan Spanholtz Ex vivo nk cell differentiation from cd34+ hematopoietic cells
AU2013251785B2 (en) 2012-04-24 2018-05-10 Dan S. Kaufman Method for developing natural killer cells from stem cells
KR101520534B1 (ko) * 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
PT3578201T (pt) 2012-06-28 2023-05-10 Univ Of Central Florida Research Foundation Incorporated Métodos e composições para células assassinas naturais
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP5856025B2 (ja) 2012-08-02 2016-02-09 阿部　博幸 単球またはｎｋ細胞を入手する方法
CN102988415B (zh) 2012-08-15 2014-11-19 中航（宁夏）生物有限责任公司 人异基因有核细胞工业化制备自然杀伤性细胞(nk)及注射液
PL2923208T3 (pl) 2012-11-21 2019-09-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi
KR101923848B1 (ko) 2013-01-15 2018-11-29 히로유키 아베 면역세포 함유 조성물의 제조방법 및 암 치료용 조성물
JP2016506968A (ja) * 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション 胎盤由来のナチュラルキラー細胞
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
KR102308597B1 (ko) 2013-10-17 2021-10-01 내셔널 유니버시티 오브 싱가포르 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
JP6588465B2 (ja) 2014-01-03 2019-10-09 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 修飾ナチュラルキラー細胞、その組成物および用途
WO2015125113A1 (en) 2014-02-21 2015-08-27 Dr. Reddy's Laboratories Limited Method of culturing high cell density pbmc's
DK3114215T3 (da) 2014-03-07 2021-06-21 Emercell Sas Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
MX389827B (es) 2014-06-11 2025-03-20 Polybiocept Gmbh Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21).
JP2016008198A (ja) 2014-06-24 2016-01-18 国立大学法人名古屋大学 間質性膀胱炎の治療
CA2954534C (en) 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
JP2016077185A (ja) 2014-10-14 2016-05-16 学校法人 聖マリアンナ医科大学 γδＴ細胞の製造方法および医薬
CN107428820B (zh) 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
WO2016109668A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
WO2016122014A1 (ko) 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CN104705291A (zh) 2015-04-03 2015-06-17 广州赛莱拉干细胞科技股份有限公司 一种脐血单个核细胞冻存液、应用、制备方法
GB201509202D0 (en) 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
WO2016209021A1 (ko) 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
KR101851270B1 (ko) 2015-07-10 2018-04-25 고려대학교 산학협력단 자연 살해세포의 대량증식 방법 및 배양용 조성물
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
CN105524880A (zh) 2016-01-27 2016-04-27 上海润泉生物技术有限公司 一种免疫细胞库的构建方法
CN107267454B (zh) 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
WO2017188790A1 (ko) * 2016-04-29 2017-11-02 고려대학교 산학협력단 저산소 조건을 이용한 면역세포의 증식 배양 방법
NZ747910A (en) 2016-05-07 2023-02-24 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
KR20240042177A (ko) 2016-10-05 2024-04-01 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
KR102623244B1 (ko) 2016-12-21 2024-01-09 주식회사 엔케이맥스 면역 세포 및 포나티닙을 포함하는 약학 조성물 및 방법
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
KR101948534B1 (ko) 2017-04-20 2019-02-15 주식회사 이뮤니스바이오 세포밀도 조절을 이용한 자연살해세포의 대량증식방법
WO2018217064A2 (ko) 2017-05-26 2018-11-29 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019046440A1 (en) 2017-08-29 2019-03-07 Flaask, Llc COMPOSITIONS AND METHODS FOR COGNITIVE, IMMUNE AND DIGESTIVE MANAGEMENT IN PATIENTS WITH AUTISM SPECTRUM DISORDER
CN107970258B (zh) 2017-11-20 2020-11-10 英普乐孚生物技术(上海)有限公司 一种嵌合抗原受体t细胞制剂
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102732845B1 (ko) 2018-02-01 2024-11-25 주식회사 엔케이맥스 자연살해세포의 생산방법
KR102765799B1 (ko) 2018-02-01 2025-02-13 주식회사 엔케이맥스 Cd56+ 자연살해세포를 포함하는 항암용 조성물
WO2019152663A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
SG11202008008UA (en) 2018-02-21 2020-09-29 Univ Texas Universal antigen presenting cells and uses thereof
WO2019168222A1 (ko) 2018-02-28 2019-09-06 주식회사 제넨셀 말초혈액단핵구 유래 항암 활성화 림프구 배양용 배지 조성물 및 이를 이용한 항암 활성화 림프구 배양방법
JP7561631B2 (ja) 2018-03-13 2024-10-04 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラ・パス 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
EP3539552A1 (en) 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
WO2019213610A1 (en) 2018-05-03 2019-11-07 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
JP2021525066A (ja) 2018-05-30 2021-09-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ Ｃａｒ ｎｋ細胞
WO2020006139A1 (en) 2018-06-27 2020-01-02 The George Washington University Targeting stat sumoylation to enhance immune responses
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN109294985B (zh) 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
EP3877509A1 (en) 2018-11-08 2021-09-15 GammaDelta Therapeutics Limited Methods for isolating and expanding cells
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
CN111205361B (zh) 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 白介素21蛋白(il21)突变体及其应用
EP3656851A1 (en) 2018-11-23 2020-05-27 Technische Universität Dresden Artificial hla-positive feeder cell lines for nk cells and uses thereof
AU2019385873A1 (en) 2018-11-26 2021-06-03 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
JP7594161B2 (ja) 2019-01-07 2024-12-04 インヒブルクス バイオサイエンシズ インコーポレイテッド 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
EP3927730A4 (en) 2019-02-20 2022-12-21 Rutgers, The State University of New Jersey EXPANSION OF NATURAL KILLER CELLS AND CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS
CU24712B1 (es) 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
AU2020254420A1 (en) 2019-03-29 2021-11-11 Board Of Regents, The University Of Texas System Methods for production of CAR-NK cells and use thereof
CA3142952A1 (en) 2019-06-25 2020-12-30 City Of Hope Pdl1 positive nk cell cancer treatment
JP2023505102A (ja) 2019-11-29 2023-02-08 エヌケーマックス カンパニー リミテッド ナチュラルキラー細胞を製造する方法およびその組成物
WO2023235806A1 (en) 2022-06-02 2023-12-07 Nkmax Co., Ltd. Method for reduction of immune checkpoint therapy related adverse events
KR20250044875A (ko) 2022-07-12 2025-04-01 주식회사 엔케이맥스 확장된 자연살해세포를 이용한 파킨슨병 치료방법
WO2024036005A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
WO2024036226A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells

Also Published As

Publication number Publication date
SG11202007221QA (en) 2020-08-28
MY199514A (en) 2023-11-02
JP7339309B2 (ja) 2023-09-05
US20210032597A1 (en) 2021-02-04
PH12020551151A1 (en) 2021-09-01
IL276365A (en) 2020-09-30
RU2020128764A (ru) 2022-03-01
US12098388B2 (en) 2024-09-24
NZ766453A (en) 2022-02-25
CN111757745A (zh) 2020-10-09
MY197176A (en) 2023-05-30
IL276365B1 (en) 2023-06-01
US10590385B2 (en) 2020-03-17
SA520412566B1 (ar) 2025-05-11
AU2021266198B2 (en) 2024-12-19
MX2021004682A (es) 2021-06-04
US20250059510A1 (en) 2025-02-20
CN111757745B (zh) 2022-11-04
CL2020002011A1 (es) 2021-02-12
CA3089853A1 (en) 2019-08-08
JP2021506333A (ja) 2021-02-22
AU2019215034A1 (en) 2020-08-27
AU2021266198A1 (en) 2021-12-02
JP2023153361A (ja) 2023-10-17
AU2019215034C1 (en) 2022-01-06
US11066644B2 (en) 2021-07-20
JP7268039B2 (ja) 2023-05-02
BR112020015512A2 (pt) 2021-01-26
EP3746095A1 (en) 2020-12-09
EP3746095A4 (en) 2021-04-21
RU2020128764A3 (enExample) 2022-03-01
CN115710576A (zh) 2023-02-24
MX2020008039A (es) 2021-09-20
US20200172869A1 (en) 2020-06-04
IL276365B2 (en) 2023-10-01
US20190345449A1 (en) 2019-11-14
AU2019215034B2 (en) 2021-08-19
JP7669434B2 (ja) 2025-04-28
JP2022000060A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
CL2020002011A1 (es) Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2021006259A2 (es) Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos
CL2020003422A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
DOP2024000207A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
NI201000016A (es) Anticuerpos humanos contra cd20 humano y método para utilizarlos.
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
MX2021013356A (es) Tratamiento y prevencion de enfermedades metabolicas.
Amatangelo et al. Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activity against multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab in vitro
CO2018012923A2 (es) Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales
CO2022000832A2 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
MX2020011263A (es) Metodos y composiciones de agotamiento de celulas t citotoxicas.
MX2019005661A (es) Método para tratar la psoriasis con el anticuerpo específico anti-il23.
CL2023003841A1 (es) Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.